Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12531609 | 0.83 | LMNA (0.40) | LMNAMTOR | |
| SCHEMBL8622800 | 0.83 | LMNA (0.40) | LMNAMTOR | |
| SCHEMBL8668421 | 0.81 | NT5E (0.36) | LMNATP53HTTHBBSTING1 | |
| SCHEMBL21225167 | 0.81 | DNMT1 (0.36) | DNMT1ADRB1GMNNALDH1A1LMNA | |
| SCHEMBL22666439 | 0.81 | DNMT1 (0.36) | DNMT1ADRB1GMNNALDH1A1LMNA | |
| SCHEMBL13376156 | 0.80 | LMNA (0.46) | DNMT1ADRB1GMNNALDH1A1LMNA | |
| SCHEMBL3115325 | 0.80 | LMNA (0.46) | DNMT1ADRB1GMNNALDH1A1LMNA | |
| SCHEMBL12729604 | 0.80 | STING1 (0.46) | STING1 | |
| SCHEMBL8620596 | 0.80 | STING1 (0.46) | STING1 | |
| SCHEMBL21049964 | 0.78 | STING1 (0.49) | ALDH1A1LMNASTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586729-B2 | Synthesis of decitabine | SCINOPHARM TAIWAN LTD. (TW) | 2013-11-19 | — | — | US | disclosed |
| US-20100087637-A1 | Synthesis of Decitabine | SCINOPHARM TAIWAN LTD. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087637-A1 | Synthesis of Decitabine | DCTD, DUT, DPYD | DNMT1 7/4885ADRB1 2635/4885GMNN 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.